Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: A report from the International PTL Consortium

Leukemia

Volumn 30, Issue 2, 2016, Pages 361-372

  Deng, L ^a   Xu Monette, Z Y ^a   Loghavi, S ^a   Manyam, G C ^b   Xia, Y ^a   Visco, C ^c   Huh, J ^d   Zhang, L ^b   Zhai, Q ^e   Wang, Y ^e   Qiu, L ^e   Dybkaer K ^f   Chiu, A ^g   Perry, A M ^h   Zhang, S ⁱ   Tzankov, A ^j   Rao, H ^k   Abramson, J ^l   Sohani, A R ^l   Xu, M ^m   Hsi, E D ⁿ   Zhu, J ^o   Ponzoni, M ^p   Wang, S ^q   Li, Ling ^r   Zhang, M ^r   Ferreri, A J M ^p   Parsons, B M ^s   Li, Y ⁿ   Piris, M A ^t   Medeiros, L J ^a   Young, K H ^a,u   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c SAN BORTOLO HOSPITAL   (Italy)

^d University of Ulsan College of Medicine   (South Korea)

^e TIANJIN MEDICAL UNIVERSITY   (China)

^f AALBORG UNIVERSITY HOSPITAL   (Denmark)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h UNIVERSITY OF MANITOBA   (Canada)

ⁱ INDIANA UNIVERSITY   (United States)

^j UNIVERSITY HOSPITAL BASEL   (Switzerland)

^k SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^l MASSACHUSETTS GENERAL HOSPITAL   (United States)

^m YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ LERNER RESEARCH INSTITUTE   (United States)

^o PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^p SAN RAFFAELE HOSPITAL   (Italy)

^q NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^r THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^s GUNDERSEN LUTHERAN MEDICAL CENTER   (United States)

^t HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^u UNIVERSITY OF TEXAS   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; PROTEIN; RITUXIMAB; T CELL LEUKEMIA LYMPHOMA 1; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXP1; UNCLASSIFIED DRUG; VINCRISTINE; FORKHEAD TRANSCRIPTION FACTOR; FOXP1 PROTEIN, HUMAN; ONCOPROTEIN; REPRESSOR PROTEIN; TCL1A PROTEIN, HUMAN;

ADULT; ADVERSE OUTCOME; AGE; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM; DISEASE SPECIFIC SURVIVAL; DRUG TREATMENT FAILURE; FOLLOW UP; GENE ACTIVATION; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIMARY TESTICULAR DIFFUSE LARGE B CELL LYMPHOMA PRIMARY TESTICULAR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL; ADOLESCENT; CHILD; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; MORTALITY; RECURRENT DISEASE; TESTICULAR NEOPLASMS; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS; RECURRENCE; REPRESSOR PROTEINS; RITUXIMAB; TESTICULAR NEOPLASMS;

EID: 84959353474     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.237     Document Type: Article

References (68)

1. Cheah CY, Wirth A, Seymour JF. Primary testicular lymphoma. Blood 2014; 123: 486-493.
2. Visco C, Medeiros LJ, Mesina OM, Rodriguez MA, Hagemeister FB, McLaughlin P, et al. Non-Hodgkin's lymphoma affecting the testis: is it curable with doxorubicinbased therapy?. Clin Lymphoma 2001; 2: 40-46.
3. Young KH, Medeiros LJ, Chan WC. Diffuse large B-cell lymphoma. In: Orazi A, Weiss LM, Foucar K, Knowles DM (eds) Neoplastic Hematopathology. Lippincott Willaims & Wilkins: Philadelphia, PA, 2014; pp 502-565.
4. Stein H, Warnke RA, Chan WC, Jaffe ES, Chan JKC, Gatter KC, et al. Diffuse large B-cell lymphoma, not otherwise specifiedIn:Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, et al. (eds) WHO Classification of Tumours of Haematopoetic and Lymphoid tissues, 4th edn. International Agency for Research on Cancer (IARC): Lyon, France, 2008; pp 233-261.
5. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
6. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, et al. Long-Term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23: 4117-4126.
7. Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 3121-3127.
8. Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379-391.
9. Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008; 9: 105-116.
10. Buskirk SJ, Evans RG, Banks PM, O'Connell MJ, Earle JD. Primary lymphoma of the testis. Int J Radiat Oncol Biol Phys 1982; 8: 1699-1703.
11. Connors JM, Klimo P, Voss N, Fairey RN, Jackson S. Testicular lymphoma: improved outcome with early brief chemotherapy. J Clin Oncol 1988; 6: 776-781.
12. Crellin AM, Hudson BV, Bennett MH, Harland S, Hudson GV. Non-Hodgkin's lymphoma of the testis. Radiother Oncol 1993; 27: 99-106.
13. Touroutoglou N, Dimopoulos MA, Younes A, Hess M, Pugh W, Cox J, et al. Testicular lymphoma: late relapses and poor outcome despite doxorubicin-based therapy. J Clin Oncol 1995; 13: 1361-1367.
14. Tondini C, Ferreri AJ, Siracusano L, Valagussa P, Giardini R, Rampinelli I, et al. Diffuse large-cell lymphoma of the testis. J Clin Oncol 1999; 17: 2854-2858.
15. Seymour JF, Solomon B, Wolf MM, Janusczewicz EH, Wirth A, Prince HM. Primary large-cell non-Hodgkin's lymphoma of the testis: a retrospective analysis of patterns of failure and prognostic factors. Clin Lymphoma 2001; 2: 109-115.
16. Mazloom A, Fowler N, Medeiros LJ, Iyengar P, Horace P, Dabaja BS. Outcome of patients with diffuse large B-cell lymphoma of the testis by era of treatment: the M. D. Anderson Cancer Center experience. Leuk Lymphoma 2010; 51: 1217-1224.
17. Wang Y, Li ZM, Huang JJ, Xia Y, Li H, Li YJ, et al. Three prognostic factors influence clinical outcomes of primary testicular lymphoma. Tumour Biol 2013; 34: 55-63.
18. Pingali S, Go RS, Gundrum JD, Wright L, Gay G. Adult testicular lymphoma in the United States (1985-2004): analysis of 3,669 cases from the National Cancer Data Base (NCDB) [abstracts]. J Clin Oncol 2008; 26: 19503 (May 20 Supplement).
19. Telio D, Villa D, Shenkier T, Sehn LH, Klasa R, Tan K, et al. Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era. Blood 2011; 118: 780.
20. Aviles A, Neri N, Huerta-Guzman J, Perez F, Fernandez R. Testicular lymphoma: organ-specific treatment did not improve outcome. Oncology 2004; 67: 211-214.
21. Vitolo U, Chiappella A, Ferreri AJ, Martelli M, Baldi I, Balzarotti M, et al. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. J Clin Oncol 2011; 29: 2766-2772.
22. Aviles A, Nambo MJ, Cleto S, Neri N, Huerta-Guzman J. Rituximab and dose-Dense chemotherapy in primary testicular lymphoma. Clin Lymphoma Myeloma 2009; 9: 386-389.
23. Linassier C, Desablens B, Lefrancq T, Le Prise PY, Harousseau JL, Jacob C, et al. Stage I-IIE primary non-Hodgkin's lymphoma of the testis: results of a prospective trial by the GOELAMS Study Group. Clin Lymphoma 2002; 3: 167-172.
24. Zucca E, Conconi A, Mughal TI, Sarris AH, Seymour JF, Vitolo U, et al. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol 2003; 21: 20-27.
25. Gundrum JD, Mathiason MA, Moore DB, Go RS. Primary testicular diffuse large B-cell lymphoma: a population-based study on the incidence, natural history, and survival comparison with primary nodal counterpart before and after the introduction of rituximab. J Clin Oncol 2009; 27: 5227-5232.
26. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.
27. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-586.
28. Xu-Monette ZY, Wu L, Visco C, Tai YC, Tzankov A, Liu WM, et al. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood 2012; 120: 3986-3996.
29. Visco C, Li Y, Xu-Monette ZY, Miranda RN, Green TM, Li Y, et al. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia 2012; 26: 2103-2113.
30. Ok CY, Li L, Xu-Monette ZY, Visco C, Tzankov A, Manyam GC, et al. Prevalence and clinical implications of Epstein-Barr virus infection in de novo diffuse large B-cell lymphoma in Western countries. Clin Cancer Res 2014; 20: 2338-2349.
31. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-282.
32. Ramuz O, Bouabdallah R, Devilard E, Borie N, Groulet-Martinec A, Bardou VJ, et al. Identification of TCL1A as an immunohistochemical marker of adverse outcome in diffuse large B-cell lymphomas. Int J Oncol 2005; 26: 151-157.
33. Tzankov A, Zlobec I, Went P, Robl H, Hoeller S, Dirnhofer S. Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores. Leuk Lymphoma 2010; 51: 199-212.
34. Larimore K, McCormick MW, Robins HS, Greenberg PD. Shaping of human germline IgH repertoires revealed by deep sequencing. J Immunol 2012; 189: 3221-3230.
35. Maurer MJ, Ghesquieres H, Jais JP, Witzig TE, Haioun C, Thompson CA, et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol 2014; 32: 1066-1073.
36. Zhang J, Chen B, Xu X. Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-Analysis. Leuk Lymphoma 2014; 55: 509-514.
37. Al-Abbadi MA, Hattab EM, Tarawneh MS, Amr SS, Orazi A, Ulbright TM. Primary testicular diffuse large B-cell lymphoma belongs to the nongerminal center B-cell-like subgroup: a study of 18 cases. Mod Pathol 2006; 19: 1521-1527.
38. Booman M, Douwes J, Glas AM, de Jong D, Schuuring E, Kluin PM. Primary testicular diffuse large B-cell lymphomas have activated B-cell-like subtype characteristics. J Pathol 2006; 210: 163-171.
39. Menter T, Ernst M, Drachneris J, Dirnhofer S, Barghorn A, Went P, et al. Phenotype profiling of primary testicular diffuse large B-cell lymphomas. Hematol Oncol 2014; 32: 72-81.
40. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-511.
41. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937-1947.
42. Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008; 359: 2313-2323.
43. Virgilio L, Narducci MG, Isobe M, Billips LG, Cooper MD, Croce CM, et al. Identification of the TCL1 gene involved in T-cell malignancies. Proc Natl Acad Sci USA 1994; 91: 12530-12534.
44. Palamarchuk A, Yan PS, Zanesi N, Wang L, Rodrigues B, Murphy M, et al. Tcl1 protein functions as an inhibitor of de novo DNA methylation in B-cell chronic lymphocytic leukemia (CLL). Proc Natl Acad Sci USA 2012; 109: 2555-2560.
45. Herling M, Patel KA, Weit N, Lilienthal N, Hallek M, Keating MJ, et al. High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia. Blood 2009; 114: 4675-4686.
46. Shin SJ, Roh J, Cha HJ, Choi YD, Kim JM, Min SK, et al. TCL1 expression predicts overall survival in patients with mantle cell lymphoma. Eur J Haematol 2015; e-pub ahead of print 17 February 2015; doi:10.1111/ejh.12539.
47. van Keimpema M, Gruneberg LJ, Mokry M, van Boxtel R, Koster J, Coffer PJ, et al. FOXP1 directly represses transcription of proapoptotic genes and cooperates with NF-kappaB to promote survival of human B cells. Blood 2014; 124: 3431-3440.
48. Sagaert X, de Paepe P, Libbrecht L, Vanhentenrijk V, Verhoef G, Thomas J, et al. Forkhead box protein P1 expression in mucosa-Associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 2490-2497.
49. Laine J, Kunstle G, Obata T, Sha M, Noguchi M. The protooncogene TCL1 is an Akt kinase coactivator. Mol Cell 2000; 6: 395-407.
50. Gualco G, Weiss LM, Barber GN, Bacchi CE. T-cell leukemia 1 expression in nodal Epstein-Barr virus-negative diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma. Hum Pathol 2010; 41: 1238-1244.
51. Wlodarska I, Veyt E, De Paepe P, Vandenberghe P, Nooijen P, Theate I, et al. FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrations. Leukemia 2005; 19: 1299-1305.
52. Barrans SL, Fenton JA, Banham A, Owen RG, Jack AS. Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome. Blood 2004; 104: 2933-2935.
53. Banham AH, Connors JM, Brown PJ, Cordell JL, Ott G, Sreenivasan G, et al. Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. Clin Cancer Res 2005; 11: 1065-1072.
54. Yu B, Zhou X, Li B, Xiao X, Yan S, Shi D. FOXP1 expression and its clinicopathologic significance in nodal and extranodal diffuse large B-cell lymphoma. Ann Hematol 2011; 90: 701-708.
55. Weng J, Rawal S, Chu F, Park HJ, Sharma R, Delgado DA, et al. TCL1: a shared tumor-Associated antigen for immunotherapy against B-cell lymphomas. Blood 2012; 120: 1613-1623.
56. Thompsett AR, Ellison DW, Stevenson FK, Zhu D. V(H) gene sequences from primary central nervous system lymphomas indicate derivation from highly mutated germinal center B cells with ongoing mutational activity. Blood 1999; 94: 1738-1746.
57. Booman M, Douwes J, Glas AM, Riemersma SA, Jordanova ES, Kok K, et al. Mechanisms and effects of loss of human leukocyte antigen class II expression in immune-privileged site-Associated B-cell lymphoma. Clin Cancer Res 2006; 12: 2698-2705.
58. Riemersma SA, Jordanova ES, Schop RF, Philippo K, Looijenga LH, Schuuring E, et al. Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immuneprivileged sites. Blood 2000; 96: 3569-3577.
59. Jordanova ES, Riemersma SA, Philippo K, Schuuring E, Kluin PM. Beta2-microglobulin aberrations in diffuse large B-cell lymphoma of the testis and the central nervous system. Int J Cancer 2003; 103: 393-398.
60. Tun HW, Personett D, Baskerville KA, Menke DM, Jaeckle KA, Kreinest P, et al. Pathway analysis of primary central nervous system lymphoma. Blood 2008; 111: 3200-3210.
61. Rubenstein JL, Fridlyand J, Shen A, Aldape K, Ginzinger D, Batchelor T, et al. Gene expression and angiotropism in primary CNS lymphoma. Blood 2006; 107: 3716-3723.
62. Sung CO, Kim SC, Karnan S, Karube K, Shin HJ, Nam DH, et al. Genomic profiling combined with gene expression profiling in primary central nervous system lymphoma. Blood 2011; 117: 1291-1300.
63. Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluqa S, Wright G, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med 2015; 21: 922-926.
64. Testoni M, Zucca E, Young KH, Bertoni F. Genetic lesions in diffuse large B-cell lymphomas. Ann Oncol 2015; 26: 1069-1080.
65. Li L, Xu-Monette ZY, Ok CY, Tzankov A, Manyam GC, Sun R, et al. Prognostic Impact of c-Rel Nuclear Expression and REL amplification and Crosstalk between c-Rel and the p53 Pathway in Diffuse Large B-Cell. Oncotarget 2015; e-pub head of print 30 June 2015.
66. Xu-Monette ZY, Dabaja BS, Wang X, Tu M, Manyam GC, Tzankov A, et al. Clinical features, tumor biology and prognosis associated with MYC rearrangement and overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Mod Pathol 2015 (in press).
67. Ok CY, Xu-Monette ZY, Li L, Manyam GC, Montes-Moreno S, Tzankov A, et al. Evaluation of NF-?B subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center Bcell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions. Mod Pathol 2015; 28: 1202-1213.
68. Hu S, Xu-Monette ZY, Tzankov A, Green T, Wu L, Balasubramanyam A, et al. MYC/ BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood 2013; 121: 4021-4031.